Fig. 1
From: The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Targeted HR-PRM-MS analyses of synaptotagmin in human CSF. Individual values for the HR-PRM-MS measured peak area ratios ((endogenous peptide/labeled peptide standard) × 1000) of immunoprecipitated synaptotagmin in CSF samples within sample set I (a, b) and sample set II (c, d). The four panels depict the measured levels of two tryptic peptides of synaptotagmin, 215–223 (VPYSELGGK) (a, c) and 238–245 (HDIIGEFK) (b, d). AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease